# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JMP Securities analyst Reni Benjamin reiterates BioAtla (NASDAQ:BCAB) with a Market Outperform and maintains $5 price target.
An ongoing complete response (CR) with an overall response rate (ORR) of 32% achieved across two dosing regimens Underscores oz...
Famed investor Michael Burry, known for his prescient bet against the housing market before the 2008 financial crisis, has made...
BioAtla (NASDAQ:BCAB) reported quarterly losses of $(0.44) per share which met the analyst consensus estimate.
Ozuriftamab vedotin, the Company's conditionally and reversibly active antibody drug conjugate directed against ROR2, has s...
JMP Securities analyst Reni Benjamin maintains BioAtla (NASDAQ:BCAB) with a Market Outperform and lowers the price target fr...
HC Wainwright & Co. analyst Arthur He reiterates BioAtla (NASDAQ:BCAB) with a Buy and maintains $7 price target.